Bullous disorders associated with anti–PD-1 and anti–PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and …
J Siegel, M Totonchy, W Damsky, J Berk-Krauss… - Journal of the American …, 2018 - Elsevier
Background Bullous disorders associated with anti–programmed cell death 1 (PD-
1)/programmed cell death ligand 1 (PD-L1) therapy are increasingly reported and may pose
distinct therapeutic challenges. Their frequency and impact on cancer therapy are not well
established. Objective To evaluate the clinical and histopathologic findings, frequency, and
impact on cancer therapy of bullous eruptions due to anti–PD-1/PD-L1 therapy. Methods We
retrospectively reviewed the medical records of patients evaluated by the oncodermatology …
1)/programmed cell death ligand 1 (PD-L1) therapy are increasingly reported and may pose
distinct therapeutic challenges. Their frequency and impact on cancer therapy are not well
established. Objective To evaluate the clinical and histopathologic findings, frequency, and
impact on cancer therapy of bullous eruptions due to anti–PD-1/PD-L1 therapy. Methods We
retrospectively reviewed the medical records of patients evaluated by the oncodermatology …